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Fatigue and exercise intolerance are common symptoms of mitochondrial diseases, but diﬃcult to be clinically assessed. New methods
to quantify these rather common complaints are strongly needed in the clinical practice. Coenzyme Q10 administration and aerobic
exercise may improve exercise intolerance, but more deﬁnite studies are still pending. Herein, we have revised “how to measure” and
“how to treat” these symptoms of mitochondrial patients. Subsequently, we reviewed the clinical data of the 1164 conﬁrmed
mitochondrial patients present in the Italian nation-wide database of mitochondrial disease, with special regard to exercise intolerance.
We observed that more of 20% of mitochondrial patients complain of exercise intolerance. This symptom seems to be frequently
associated with speciﬁc patient groups and/or genotypes. Ragged red ﬁbers and COX-negative ﬁbers are more often present in subjects
with exercise intolerance, whereas lactate levels could not predict this symptom. Multicenter eﬀorts are strongly needed for rare disorders
such as mitochondrial diseases, and may represent the basis for more rigorous longitudinal studies.
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The most crucial task of the mitochondrion is the gener-
ation of energy as adenosine triphosphate, by means of the
electron transport chain [1]. This pathway is under control
M. Mancuso et al. / Neuromuscular Disorders 22 (2012) S226–S229 S227of both nuclear and mitochondrial (mtDNA) genomes.
Mitochondrial diseases are a group of disorders caused
by impairment of the respiratory chain. They are one of
the commonest inherited neuromuscular diseases, with an
estimated prevalence of 1–2 in 10,000. The genetic classiﬁ-
cation distinguishes the disorders due to defects in mtDNA
from those due to defects in nuclear DNA. The eﬀects of
mutations which aﬀect the respiratory chain may be multi-
systemic, with possible involvement of visual and auditory
pathways, heart, central nervous system, and skeletal mus-
cle [1]. The “red ﬂags” of mitochondrial diseases are myo-
pathic signs and symptoms (including fatigue and exercise
intolerance), eyelid ptosis, ophthalmoparesis, axonal multi-
focal neuropathy, sensorineural hearing loss, pigmentary
retinopathy, optic neuropathy, diabetes mellitus, hypertro-
phic cardiomyopathy, migraine, short stature [2].
Experienced fatigue may be deﬁned as an overwhelming
sense of tiredness, lack of energy and feeling of exhaustion.
More speciﬁcally, muscle fatigue with exercise intolerance
is a multifactorial process characterized by failure to main-
tain an expected level of force during sustained or repeated
muscle contraction, and is considered a common symptom
of mitochondrial diseases. It is putatively due to an
increased skeletal muscle dependence on anaerobic metab-
olism, with increased lactate and free radical generation,
phosphocreatine (PCr) depletion, reduced oxygen extrac-
tion. At the whole body level, this is characterized by a
reduction in maximal oxygen consumption (VO2) with
excessive carbon dioxide production (VCO2), increased rat-
ing of perceived exertion and hyperdynamic circulatory
response at a given exercise intensity [3].
2. How to measure fatigue and exercise intolerance in
mitochondrial patients?
Exercise intolerance is diﬃcult to be clinically assessed
and quantiﬁed. Classically, the characterization of exercise
intolerance is performed using cycloergometry with mea-
surements of VO2, VCO2, respiratory exchange ratio, heart
rate, minute ventilation, rating of perceived exertion, and
cardiac output [3]. Taivassalo and co-workers [4] evaluated
oxidative capacity and circulatory and ventilatory
responses to maximal cycle exercise in 40 patients with bio-
chemically and/or molecularly deﬁned mitochondrial myo-
pathies associated with variable degrees of exercise
tolerance, comparing those responses with healthy seden-
tary individuals results. In mitochondrial patients, mean
peak work capacity and VO2 were signiﬁcantly lower than
in controls, but the range was quite broad [4]. Oxidative
capacity in patients was limited by the ability of muscle
to extract available oxygen from blood, as indicated by a
linear correlation between peak VO2 and peak systemic
arterovenous O2 diﬀerence. In the patients group, the
increase in cardiac output relative to VO2 and ventilation
was increased compared to controls. In patients with het-
eroplasmic mtDNA mutations, an inverse relationship
between the proportion of skeletal muscle mutant mtDNAand peak extraction of available O2 during exercise was
observed [4]. Another study [5] showed that the severity
of oxidative impairment (as assessed during cycloergometer
exercise) closely correlated with venous O2 levels during
forearm exercise, which resulted paradoxically increased
in these patients. This may reﬂect a blunted ability of work-
ing muscle to extract O2, resulting in high O2 delivery rela-
tive to use, high tissue O2 content, and elevated O2 levels in
venous eﬄuent [5].
From a biochemical perspective, in patients with sus-
pected mitochondrial disease, lactate increase after eﬀort
is commonly measured and has diagnostic use [2]. How-
ever, the role of lactate in the development of exercise intol-
erance in these patients is unclear. In a double-blinded,
placebo-controlled, crossover study in seven patients with
mitochondrial myopathy, lowering of lactate with dichlo-
roacetate could not improve exercise tolerance and oxida-
tive capacity, suggesting that lactate is not the primary
cause of exercise intolerance [6]. A biochemical study could
not demonstrate any diﬀerence between healthy controls
and mitochondrial patients; consecutive 60-min microdi-
alysis samples were taken from the tibialis anterior muscle
in eleven healthy subjects and four patients with mitochon-
drial myopathy, before and after sustained isometric foot
dorsi-ﬂexions [5]. Before exercise, mean concentrations of
lactate, pyruvate, hypoxanthine, urate, aspartate, and glu-
tamate did not diﬀer between controls and patients. After
exercise, both groups showed increased concentrations of
lactate, pyruvate, and urate, decreased hypoxanthine, and
no change in aspartate and glutamate [5]. Exercise-induced
increase in integrated electromyogram amplitude and rated
subjective fatigue were correlated to increased post-exercise
lactate concentrations, with no diﬀerences between the two
groups. This experimental apparatus could allow the detec-
tion and monitoring of biochemical changes in the intersti-
tial space, but larger studies should be performed [5].
Oxidative stress may also have a role [7], but further studies
are needed.
Another approach to measure fatigue is the use of
magnetic resonance spectroscopy (MRS), a frequency
analysis of the MR signal that allows an evaluation of
brain and muscle metabolism in vivo [2]. Phosphorous
(31P) MRS measures PCr and inorganic phosphate (Pi)
ﬂuctuations during muscle exercise, thus monitoring oxi-
dative metabolism. The most useful indicators of mito-
chondrial disease are combined low PCr/Pi ratio at rest
and low post-exercise recovery, and delay in post exercise
adenosine diphosphate (ADP) recovery. Nevertheless, 31P
MRS of skeletal muscle does not seem to be a sensitive
diagnostic test for mitochondrial myopathy [2]. In a study
of seven patients with single large-scale deletion, nine with
mtDNA point mutations and 14 healthy subjects, PCr/Pi
and ATP production after exercise was similar in patients
and healthy subjects [8]. For these reasons, muscular 31P
MRS is still experimental in clinical practice, but could
potentially be a useful tool for monitoring the response
to therapies.
Table 1
Genotype-based approach. The patients have been divided in two groups,
with and without exercise intolerance. For more details, see text. n.s., not
signiﬁcant diﬀerence. LHON: Leber hereditary optic neuropathy.
Exercise
intolerance:
No (n = 878)
Exercise
intolerance:
Yes (222)
P
mtDNA A3243G mutation 62 (7.1%) 33 (14.9%) <0.0005
mtDNA A8344G mutation 27 (3.1%) 9 (4.1%) n.s.
mtDNA T8993C 19 (2.2%) 1 (0.5%) n.s.
mtDNA LHON mutations 98 (11.2%) 1 (0.5%) <0.0001
OPA1 mutations 85 (9.7%) 1 (0.5%) <0.0001
POLG mutations 33 (3.8%) 8 (3.6%) n.s.
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mitochondrial diseases?
The treatment of mitochondrial diseases is still inade-
quate, despite great progress in the molecular understand-
ing of these disorders. Therapies that have been attempted
include respiratory chain cofactors and other metabolites
and antioxidants, but their role in the treatment of the
majority of these patients remains unclear. However, a ran-
domized trial reported that 60 days of coenzyme Q10
(1200 mg/day) treatment had minor but signiﬁcant positive
eﬀects on cycle exercise aerobic capacity (with signiﬁcant
increase in VO2) and post-exercise lactate, even though it
did not aﬀect other clinically relevant variables such as
strength or resting lactate [9].
Several studies have found that supervised aerobic activ-
ity can improve exercise capacity, reduce lactate and
improve ADP recovery kinetics using MRS [3]. The eﬀect
of 12 weeks cycle training on exercise capacity, quality of
life and underlying molecular and cellular events have been
studied in 20 mitochondrial patients and 13 healthy sub-
jects [10]. After the training, maximum VO2 and muscle cit-
rate synthase increased in patients and healthy controls,
while mtDNA quantity in muscle only increased in the
patient group. Therefore, aerobic training could eﬃciently
improve oxidative capacity in patients with mitochondrial
myopathy, and regular aerobic exercise may be recom-
mended in these subjects [10].
4. The experience of the Italian Mitochondrial Registry
Network
Based on the database of the “Nation-wide Italian Col-
laborative Network of Mitochondrial Diseases”, we pre-
liminarily reviewed the clinical data of the 1164
histologically, biochemically and/or molecularly deﬁned
patients present in our database (June 18th, 2012) and fol-
lowed in the diﬀerent Centers, with special regard to exer-
cise intolerance.
The database establishment (and its use for scientiﬁc
purposes) was permitted by the local Ethical Committees
of the single Centers, which obtained the patients’ written
consent, and has been performed in accordance with the
ethical standards laid down in the 1964 Declaration of Hel-
sinki. It has been supported by a Telethon Grant
(GUP09004).
Data were expressed as means ± standard deviation.
Comparisons of proportions have been performed by
Chi-square test. A P value <0.05 was considered as signif-
icant. Data analysis was carried out using MedCalc
Version 7.3.0.1.
The clinical picture was fully available for 1100 patients
(mean age at onset 24.4 ± 20.5 years; age at last evaluation
39.8 ± 22.3 years; females 51.0%; childhood onset [before
age 16-yrs] 43.8%). Exercise intolerance was part of the
clinical picture in 222/1100 patients (20.2%), being
the fourth clinical manifestation in term of frequency inthese patients after ptosis/ophthalmoparesis, muscle weak-
ness and hearing loss. In 108 of them, exercise intolerance
was one of the presenting symptoms at the onset of the
disease.
In order to understand if the presence (or absence) of
exercise intolerance was linked with speciﬁc molecular or
pathological features, the patients of the Registry have
been divided in two groups, with and without exercise
intolerance. Age at onset, age at last evaluation and gender
ratio did not signiﬁcantly diﬀer between the two groups.
From a genotype-based approach (Table 1), the com-
mon mtDNA A3243G mutation associated with MELAS
(mitochondrial encephalomyopathy with lactic acidosis
and stroke-like episodes) and other clinical phenotypes,
was less present in the group without than one with exercise
intolerance (P < 0.0005). Exercise intolerance was reported
in 33/95 (34.7%) of the A3243G patients of our database.
The other common mtDNA change, the A8344G
“MERRF” (myoclonic epilepsy with ragged red ﬁbers)
mutation, showed the same frequency in the two groups.
From the opposite perspective, 9/36 (25.0%) A8344G
patients complained of exercise intolerance.
The mtDNA T8993C mutation, associated with NARP
(neuropathy, ataxia, retinitis pigmentosa) and with mater-
nally-inherited Leigh syndrome, was more common in the
group without than with exercise intolerance, but the diﬀer-
ence did not reach statistical signiﬁcance. Only 1/20 of the
T8993A patients complained of exercise intolerance. As
expected, patients with genetically-conﬁrmed Leber hered-
itary optic neuropathy (LHON) were far more common in
the group without than with intolerance (P < 0.0001). The
same was observed for OPA1 gene mutations, the most
common cause of autosomal dominant optic atrophy
(ADOA). POLG gene mutations had the same frequency
in the two groups; 8/41 (19.8%) POLG patients complained
of exercise intolerance.
From a phenotype-based approach, patients with PEO
phenotype were more common in the group with exercise
intolerance (87/222 [39.2%] versus 247/878 [28.1%],
P < 0.002); 87/334 (26.0%) of patients with PEO reported
exercise intolerance. Leigh syndrome was more common
in the group without exercise intolerance (72/878 [8.2%]
versus 5/222 [2.3%], P < 0.005). Probably, in these young
M. Mancuso et al. / Neuromuscular Disorders 22 (2012) S226–S229 S229patients, the subtle symptom “exercise intolerance” is
hidden by the devastating neurodegenerative phenotype.
From a clinical perspective, as expected, muscle weakness
was less frequent in the patients without (255/878, 29.0%)
than with (155/222, 69.8%) exercise intolerance
(P < 0.0001). The same ﬁnding was also observed when con-
sidering all the other myopathic signs included in our data-
base: muscle pain (6.5% versus 27.0%, P < 0.0001), muscle
wasting (14.6% versus 30.2%, P < 0.0001), eyelid ptosis/
ophthalmoparesis (38.8% versus 58.6%,P < 0.0001), cardio-
myopathy (4.9% versus 17.1%, P < 0.0001), increased
plasma creatine kinase (CK) levels (12.6% versus 34.2%,
P < 0.0001).
In those patients in whom muscle biopsy has been per-
formed, ragged red ﬁbers were less common in the group
without (311/484, 64.3%) than with (127/169, 75.1%) exer-
cise intolerance (P < 0.05). The same was observed for
COX (cytochrome c oxidase)-negative ﬁbers, with a stron-
ger statistical signiﬁcance (295/484 [61.0%] versus 124/169
[73.4%] (P  0.005). Finally, considering the patients for
whom plasma lactate levels were available, this biomarker
was increased in 269/502 (53.6%) patients without exercise
intolerance and in 89/175 (50.9%) patients with exercise
intolerance (P not signiﬁcant).
5. Conclusions
Exercise intolerance and fatigue are diﬃcult to assess
clinically and remain an elusive symptom, even in the neu-
romuscular setting. New methods to quantify these rather
common complaints are strongly needed in the clinical
practice. Here we showed that more of 20% of mitochon-
drial patients complain of exercise intolerance. This symp-
tom seems more strongly associated with speciﬁc mutations
(i.e., A3243G). CK levels were increased in 34% of the
patients with exercise intolerance, not conﬁrming the
notion that CK levels are normal in the great majority of
mitochondrial patients [2]. Moreover, all the other myo-
pathic signs included in our database (muscle pain, muscle
wasting, eyelid ptosis/ophthalmoparesis, cardiomyopathy)
were associated with exercise intolerance. Ragged red ﬁbers
and, especially, COX-negative ﬁbers were more frequent in
the subjects with exercise intolerance, whereas lactate levels
failed to predict the presence of exercise intolerance. Lac-
tate is the most common marker of mitochondrial dysfunc-
tion in the clinical practice [2], but additional, possibly
more reliable, markers are still strongly needed.
Admittedly, this survey presents the typical limitations
of all retrospective studies, and probably underestimates
the real prevalence of exercise intolerance in patients with
mitochondrial diseases, being a symptom that sometimes
could be missed when not actively searched. However,
similar multicenter eﬀorts are strongly needed for rare
disorders such as mitochondrial diseases, and can prompt
to more rigorous longitudinal studies. Multicenter studiesare also needed to better characterize the clinical picture
and natural history of these diseases, and identify pharma-
cological, physical, or other countermeasures capable
to beneﬁt the patients suﬀering with these chronic, still
incurable disorders.
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